Sugemalimab (DB16641): A Comprehensive Monograph on a Novel PD-L1 Immune Checkpoint Inhibitor

Executive Summary

Sugemalimab is a novel, fully human, full-length immunoglobulin G4 (IgG4) monoclonal antibody that targets the programmed death-ligand 1 (PD-L1), a critical immune checkpoint protein. Developed by CStone Pharmaceuticals, Sugemalimab represents a significant advancement in the field of immuno-oncology, characterized by a sophisticated molecular design, a robust clinical development program, and a rapidly expanding global regulatory footprint. Marketed under the trade names Cejemly and Eqjubi, it has demonstrated substantial efficacy across a wide spectrum of malignancies.

The therapeutic activity of Sugemalimab is driven by a dual mechanism of action. It not only blocks the interaction between PD-L1 on tumor cells and the PD-1 receptor on T-cells, thereby restoring the body's natural anti-tumor immune response, but it also induces antibody-dependent cellular phagocytosis (ADCP), providing a secondary pathway for tumor cell destruction. Critically, its IgG4 isotype was engineered to lack antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), a feature designed to enhance its safety profile by preventing the elimination of valuable PD-L1-expressing T-cells.

The extensive GEMSTONE clinical trial program has provided compelling evidence of Sugemalimab's efficacy and safety. In non-small cell lung cancer (NSCLC), it has shown significant survival benefits as a first-line treatment for metastatic (Stage IV) disease irrespective of PD-L1 expression levels and as a consolidation therapy for unresectable (Stage III) disease in a broad patient population. Furthermore, Sugemalimab has achieved landmark first-in-class approvals for the treatment of relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL), first-line esophageal squamous cell carcinoma (ESCC), and first-line gastric cancer, indications with high unmet needs, particularly in Asian populations.

This clinical success has translated into a series of major regulatory approvals. After establishing a strong foundation with five distinct approvals from China's National Medical Products Administration (NMPA), Sugemalimab has successfully entered the European market with approvals from the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for metastatic NSCLC. While it has received Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), full marketing authorization in the United States remains a future objective.

This report provides a comprehensive analysis of Sugemalimab, detailing its molecular and pharmacological properties, dissecting the pivotal clinical trial data that support its use, evaluating its safety profile, and mapping its global regulatory and competitive landscape. The evidence collectively positions Sugemalimab as a differentiated and highly effective immune checkpoint inhibitor, poised to play a significant role in the treatment of multiple cancers worldwide and exemplifying the growing impact of global biopharmaceutical innovation.

Molecular Profile and Mechanism of Action

Drug Identification and Physicochemical Properties

Sugemalimab is a protein-based biotherapeutic agent with a complex molecular structure and specific identifiers that define its place in pharmacological and regulatory databases.

• Generic Name: Sugemalimab [1]
• Trade Names: Cejemly (in China and the European Union), Eqjubi (in the United Kingdom) [2]
• Developmental Codes: CS-1001, WBP-315 [2]
• Primary Identifiers:
• DrugBank ID: DB16641 [User Query]
• CAS Number: 2256084-03-2 [3]

Sugemalimab is classified as a fully human, full-length anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb).[1] It is produced using recombinant DNA technology within Chinese Hamster Ovary (CHO) cells, a standard industry platform for manufacturing therapeutic proteins.[1] The molecular weight of the antibody is approximately 143.33 kDa to 143.36 kDa.[3] It is important to note that some databases, such as PubChem, may erroneously associate Sugemalimab's identifiers with a small molecule formula (e.g., C6H11ClN2); this is incorrect, as Sugemalimab is a large protein therapeutic comprising multiple amino acid chains.[8]

The molecule was discovered by CStone Pharmaceuticals utilizing the OmniRat® transgenic animal platform. This technology enables the direct generation of fully human antibodies, a key feature intended to minimize the potential for immunogenicity when administered to patients.[10] The development of Sugemalimab has been a collaborative effort involving CStone Pharmaceuticals as the originator, along with partners such as Bayer and EQRx.[12]

Dual-Mechanism Immune Activation

The anti-tumor activity of Sugemalimab is rooted in a sophisticated, dual-pronged mechanism of action that both unleashes the patient's adaptive immune system and engages the innate immune system to target and destroy cancer cells.

Primary Mechanism: PD-1/PD-L1 Axis Blockade

The foundational mechanism of Sugemalimab is its function as an immune checkpoint inhibitor. Many cancer cells evade destruction by the immune system by overexpressing PD-L1 (also known as Cluster of Differentiation 274 or B7-H1) on their surface.[2] This ligand binds to the programmed cell death protein 1 (PD-1) receptor, a transmembrane protein found on activated T-cells.[8] The engagement of PD-1 by PD-L1 delivers a potent inhibitory signal to the T-cell, effectively deactivating it and preventing it from recognizing and attacking the tumor cell. This process of "T-cell exhaustion" is a primary mechanism of immune escape for many malignancies.[2]

Sugemalimab is designed to specifically target and bind to the PD-L1 protein on tumor cells. This high-affinity binding physically obstructs the interaction between PD-L1 and its receptors, PD-1 and CD80 (B7-1).[2] By blocking this inhibitory pathway, Sugemalimab effectively removes the "brakes" on the anti-tumor immune response. This action reverses T-cell inactivation, restoring and enhancing the cytotoxic T-lymphocyte (CTL)-mediated attack against cancer cells. The reactivation of T-cells leads to their proliferation and an increased production of crucial effector cytokines, such as interferon-gamma (

IFN−γ) and interleukin-2 (IL−2), which further amplify the immune assault on the tumor.[4]

Secondary and Differentiating Mechanisms

Beyond its primary function as a checkpoint blocker, the molecular architecture of Sugemalimab confers additional anti-tumor properties while simultaneously being engineered for an improved safety profile. This strategic molecular design aims to create a superior therapeutic index by maximizing efficacy while minimizing on-target, off-tumor toxicities.

The choice of an IgG4 isotype for the antibody's backbone is a deliberate and critical design feature. While some antibody isotypes (like IgG1) are potent inducers of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), the IgG4 isotype naturally possesses minimal or no such activity.[1] This is advantageous because PD-L1 is also expressed on the surface of activated T-cells, which are the very cells required for an effective anti-tumor response. An antibody with strong ADCC/CDC activity could inadvertently target and destroy these essential T-cells in a process known as "T-cell fratricide," thereby undermining its own therapeutic effect. By engineering Sugemalimab to lack ADCC/CDC, the risk of this unwanted on-target toxicity is mitigated, helping to preserve the T-cell population essential for killing cancer cells and potentially leading to a more favorable safety profile.[1]

Concurrently, Sugemalimab's design enables a distinct and complementary secondary mechanism: the induction of antibody-dependent cellular phagocytosis (ADCP).[1] The Fc region of the Sugemalimab antibody, while inert for ADCC/CDC, can still be recognized by Fc receptors on phagocytic cells, most notably tumor-associated macrophages (TAMs). When Sugemalimab binds to PD-L1 on a tumor cell, it effectively "tags" the cell for destruction. This allows it to act as a bridge, cross-linking the PD-L1-expressing tumor cell with a nearby macrophage. This engagement triggers the macrophage to engulf and digest the cancer cell.[11] ADCP therefore represents a second, T-cell-independent pathway through which Sugemalimab can mediate tumor cell killing, adding another layer to its anti-neoplastic activity.

The fully human nature of the antibody, derived from the OmniRat® platform, is another key aspect of its design. Chimeric or humanized antibodies contain non-human protein sequences that can be recognized as foreign by the patient's immune system, leading to the formation of anti-drug antibodies (ADAs). ADAs can neutralize the drug, reducing its efficacy over time, and can also increase the risk of infusion-related reactions and other immune-mediated adverse events. By being fully human, Sugemalimab is designed to have low immunogenicity, which is expected to translate into more consistent and durable efficacy and a better long-term safety profile, a particularly important attribute for a therapy administered over many cycles in the oncology setting.[10]

Pharmacological Profile

The clinical application of Sugemalimab is guided by a thorough understanding of its pharmacological properties, specifically its pharmacokinetics (the body's effect on the drug) and pharmacodynamics (the drug's effect on the body).

Pharmacokinetics (PK)

A comprehensive population pharmacokinetic (PopPK) analysis, which pooled data from 1,628 patients across nine Phase I to Phase III clinical studies, has provided a detailed characterization of Sugemalimab's behavior in the human body.[17]

• Pharmacokinetic Model: The analysis concluded that the PK profile of Sugemalimab is best described by a two-compartment model with first-order elimination. A notable finding from this model was the identification of time-varying clearance, which suggests that the rate at which the drug is cleared from the body changes over the course of treatment.[17] This phenomenon is often indicative of target-mediated drug disposition (TMDD), a characteristic of high-affinity monoclonal antibodies. Initially, when the tumor burden and the number of PD-L1 targets are high, a substantial portion of the drug is eliminated through binding to and internalization with its target. As the therapy effectively reduces the tumor mass, this target-mediated clearance pathway becomes saturated or diminishes, leading to a slower overall clearance rate and a longer drug half-life. This provides a strong pharmacological rationale for the drug's on-target activity and supports the robustness of its dosing schedule.
• Absorption and Bioavailability: As Sugemalimab is administered via intravenous (IV) infusion, it is immediately and completely available in the systemic circulation, resulting in 100% bioavailability.[1]
• Distribution: The drug exhibits a relatively small volume of distribution at steady-state (Vss), with a geometric mean of 5.56 L (CV% of 21%).[1] This indicates that Sugemalimab is primarily confined to the plasma and interstitial fluid compartments and does not distribute extensively into deep tissues.
• Metabolism and Elimination: Consistent with other therapeutic monoclonal antibodies, Sugemalimab is not metabolized by hepatic cytochrome P450 enzymes and does not undergo renal excretion. Instead, it is cleared from the body through general protein catabolism via non-specific pathways, such as lysosomal degradation within the reticuloendothelial system.[1]
• Covariate Analysis: The PopPK model investigated the influence of numerous patient-specific factors on the drug's pharmacokinetics. The analysis revealed statistically significant relationships between Sugemalimab clearance and several covariates: body weight, serum albumin levels, gender, the presence of anti-drug antibodies (ADAs), tumor burden, and tumor type.[17] However, subsequent simulations demonstrated that the magnitude of the effect of these covariates on overall drug exposure was less than 20%. This level of variability is not considered clinically meaningful. Consequently, the analysis concluded that dose adjustments based on these demographic or baseline disease characteristics are not necessary.[17] This finding represents a significant practical and commercial advantage, as it allows for a simplified, fixed-dose regimen (1200 mg every 3 weeks) for all patients, which reduces the complexity of prescribing and administration, minimizes the potential for dosing errors, and enhances its clinical utility.

Pharmacodynamics (PD)

Pharmacodynamics describes the relationship between drug concentration and its pharmacological effect.[19] For Sugemalimab, the primary pharmacodynamic effect is the sustained blockade of the PD-1/PD-L1 interaction at the tumor site. The pharmacokinetic profile ensures that therapeutic concentrations of Sugemalimab are maintained in the plasma over the 3-week dosing interval, leading to continuous target engagement and sustained reactivation of the anti-tumor T-cell response.

While detailed clinical pharmacodynamic biomarker data were not extensively covered in the provided materials, preclinical studies have elucidated the downstream effects of PD-L1 blockade by Sugemalimab. These studies demonstrated that the antibody effectively induces the proliferation of CD4+ T lymphocytes and enhances the production of key pro-inflammatory cytokines, including interferon-γ and interleukin-2.[4] Furthermore, Sugemalimab was shown to favorably modulate the tumor microenvironment by increasing the ratio of cytotoxic T-cells to immunosuppressive regulatory T-cells, promoting the polarization of macrophages towards an anti-tumor (M1) phenotype, and reducing the population of myeloid-derived suppressor cells (MDSCs).[4] These cellular changes are the mechanistic underpinnings of the clinical efficacy observed in human trials.

The GEMSTONE Clinical Development Program: A Trial-by-Trial Analysis

The clinical validation of Sugemalimab is anchored in the GEMSTONE program, a series of large-scale, pivotal clinical trials designed to evaluate its efficacy and safety across a range of cancers and clinical settings. These trials have provided the foundational evidence for its multiple regulatory approvals.

Table 1: Summary of Pivotal GEMSTONE Clinical Trials

Trial Name (NCT ID)	Phase	Indication / Patient Population	N	Intervention Arm vs. Control Arm	Primary Endpoint(s)	Key Efficacy Outcome
GEMSTONE-302 (NCT03789604)	III	1L Metastatic (Stage IV) NSCLC	479	Sugemalimab + Chemo vs. Placebo + Chemo	PFS	Median OS: 25.4 vs. 16.9 mo (HR 0.68)
GEMSTONE-301 (NCT03728556)	III	Unresectable (Stage III) NSCLC (Consolidation)	381	Sugemalimab vs. Placebo	PFS	Median PFS (sCRT): 8.1 vs. 4.1 mo (HR 0.57)
GEMSTONE-303 (NCT03802591)	III	1L G/GEJ Adenocarcinoma (PD-L1 CPS ≥5)	479	Sugemalimab + CAPOX vs. Placebo + CAPOX	OS & PFS	Median OS: 15.6 vs. 12.6 mo (HR 0.75)
GEMSTONE-304 (NCT04187352)	III	1L Esophageal Squamous Cell Carcinoma (ESCC)	540	Sugemalimab + Chemo vs. Placebo + Chemo	OS & PFS	Median OS: 15.3 vs. 11.5 mo (HR 0.70)
GEMSTONE-201 (NCT03952206)	II	Relapsed/Refractory Extranodal NK/T-cell Lymphoma (R/R ENKTL)	80	Sugemalimab Monotherapy	ORR	ORR: 44.9%; CR Rate: 35.9%
1L: First-Line; NSCLC: Non-Small Cell Lung Cancer; G/GEJ: Gastric/Gastroesophageal Junction; sCRT: sequential Chemoradiotherapy; Chemo: Chemotherapy; CAPOX: Capecitabine and Oxaliplatin; PFS: Progression-Free Survival; OS: Overall Survival; ORR: Objective Response Rate; CR: Complete Response; HR: Hazard Ratio.

GEMSTONE-302: Metastatic Non-Small Cell Lung Cancer (Stage IV)

The GEMSTONE-302 trial was a randomized, double-blind, Phase III study that established Sugemalimab as a first-line treatment for metastatic NSCLC.[20] The trial enrolled 479 patients with previously untreated Stage IV squamous or non-squamous NSCLC who did not have sensitizing EGFR, ALK, ROS1, or RET genomic tumor aberrations.[2] Patients were randomized 2:1 to receive either Sugemalimab (1200 mg IV every 3 weeks) in combination with standard platinum-based chemotherapy or a placebo plus chemotherapy.[20] The primary endpoint was progression-free survival (PFS) as assessed by investigators, with overall survival (OS) as a key secondary endpoint.[10]

The trial met its primary and key secondary endpoints, demonstrating a statistically significant and clinically meaningful improvement in survival.

• Progression-Free Survival: The final PFS analysis showed a median PFS of 9.0 months in the Sugemalimab arm compared to 4.9 months in the placebo arm, corresponding to a hazard ratio (HR) of 0.48 (p<0.0001).[22]
• Overall Survival: Long-term follow-up revealed a median OS of 25.4 months for patients receiving Sugemalimab versus 16.9 months for those receiving placebo (HR 0.68), representing a 32% reduction in the risk of death.[24] The 4-year OS rate was more than double in the investigational arm, at 32.1% versus 17.3% for placebo.[24]

A critical finding from GEMSTONE-302 was the consistency of the survival benefit across all predefined patient subgroups. The improvements in PFS and OS were observed regardless of tumor histology (squamous vs. non-squamous) and, importantly, irrespective of the patient's PD-L1 expression level.[21] This "all-comer" efficacy is a significant clinical advantage, as it positions Sugemalimab as a highly effective first-line option for a broad population of metastatic NSCLC patients without the need for PD-L1 biomarker testing to determine eligibility, thereby simplifying the treatment decision-making process for oncologists.

GEMSTONE-301: Unresectable Non-Small Cell Lung Cancer (Stage III)

The GEMSTONE-301 study was a randomized, double-blind, Phase III trial designed to evaluate Sugemalimab as a consolidation therapy for patients with locally advanced, unresectable Stage III NSCLC.[22] The trial enrolled 381 patients whose disease had not progressed following completion of chemoradiotherapy. Patients received either Sugemalimab (1200 mg IV every 3 weeks) or a placebo for up to 24 months.[22]

A key strategic element of this trial's design was its inclusion of patients who had received either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT). This contrasts with the pivotal PACIFIC trial of durvalumab, which was limited to patients who had received cCRT.[26] As many patients are unable to tolerate the toxicity of cCRT, the GEMSTONE-301 trial was designed to address the unmet need in the sCRT population and provide evidence for a broader patient group.

The trial successfully met its primary endpoint of PFS.

• Progression-Free Survival: Sugemalimab demonstrated a significant improvement in PFS compared to placebo. In the final analysis, the benefit was evident in both chemoradiotherapy subgroups. For patients who received cCRT, the median PFS was 15.7 months with Sugemalimab versus 8.3 months with placebo (HR=0.71). For the sCRT population, the benefit was also pronounced, with a median PFS of 8.1 months versus 4.1 months (HR=0.57).[27]
• Overall Survival: Initial analyses showed a strong trend favoring Sugemalimab (HR 0.4), though the data were immature at the time of the first report.[22]

The positive results in both the cCRT and sCRT cohorts validate Sugemalimab as an effective consolidation therapy for a wider and more representative real-world population of Stage III NSCLC patients.

GEMSTONE-303: Gastric & Gastroesophageal Junction (G/GEJ) Adenocarcinoma

The GEMSTONE-303 trial was a randomized, double-blind, Phase III study that established Sugemalimab as a first-line treatment for a specific subset of patients with advanced gastric cancer.[28] The study enrolled 479 treatment-naïve patients with unresectable locally advanced or metastatic G/GEJ adenocarcinoma whose tumors expressed PD-L1 with a Combined Positive Score (CPS) of 5 or greater.[28] Patients were randomized to receive Sugemalimab (1200 mg IV every 3 weeks) in combination with CAPOX chemotherapy (capecitabine and oxaliplatin) or a placebo plus CAPOX.[28] The co-primary endpoints were OS and PFS.[28]

The trial successfully met both primary endpoints, demonstrating significant clinical benefit.

• Overall Survival: The median OS was 15.6 months in the Sugemalimab arm compared to 12.6 months in the placebo arm (HR 0.75; p=0.006).[28]
• Progression-Free Survival: The median PFS was 7.6 months with Sugemalimab versus 6.1 months with placebo (HR 0.66; p<0.001).[29]
• High PD-L1 Expressors: The survival benefit was even more pronounced in patients with a higher level of PD-L1 expression (CPS ≥10), where the median OS was 17.8 months versus 12.5 months (HR 0.64).[30]

These results led to Sugemalimab becoming the world's first anti-PD-L1 antibody approved for the first-line treatment of G/GEJ adenocarcinoma, establishing a new standard of care for this patient population.[32]

GEMSTONE-304: Esophageal Squamous Cell Carcinoma (ESCC)

The GEMSTONE-304 trial was a randomized, double-blind, Phase III study evaluating Sugemalimab in the first-line treatment of advanced ESCC.[33] The trial enrolled patients with unresectable locally advanced, recurrent, or metastatic ESCC, randomizing them to receive either Sugemalimab plus standard chemotherapy (5-fluorouracil and cisplatin) or a placebo plus chemotherapy.[33] The study was designed with dual primary endpoints of PFS and OS.[34]

The study met both of its primary endpoints, demonstrating significant improvements in survival.

• Overall Survival: The median OS was 15.3 months for patients in the Sugemalimab arm compared to 11.5 months in the placebo arm (HR 0.70; p=0.0076).[33]
• Progression-Free Survival: The median PFS was 6.2 months with Sugemalimab versus 5.4 months with placebo (HR 0.67; p=0.0002).[33]
• Subgroup Analysis: Consistent with findings in other trials, the clinical benefit was observed across almost all predefined subgroups, including those with different levels of PD-L1 expression.[33]

The success of GEMSTONE-304 resulted in Sugemalimab becoming the world's first anti-PD-L1 monoclonal antibody approved for the first-line treatment of ESCC, addressing a major unmet medical need, particularly in China and other parts of Asia where ESCC is highly prevalent.[33]

GEMSTONE-201: Relapsed/Refractory Extranodal NK/T-cell Lymphoma (R/R ENKTL)

The GEMSTONE-201 study was a single-arm, multicenter, Phase II registrational trial that evaluated Sugemalimab as a monotherapy for a rare and aggressive hematologic malignancy.[37] The study enrolled patients with R/R ENKTL who had previously failed treatment with an asparaginase-based chemotherapy regimen.[38] The primary endpoint was the objective response rate (ORR) as assessed by an Independent Radiology Review Committee (IRRC).[38]

The study demonstrated remarkable and durable anti-tumor activity.

• Objective Response Rate: The IRRC-assessed ORR was 44.9%. Notably, the complete response (CR) rate was very high at 35.9%, indicating deep and meaningful responses to treatment.[37]
• Duration of Response: The responses were exceptionally durable. The median duration of response (DoR) was not reached at the time of analysis, and the 12-month DoR rate was 82.5%.[37]

These powerful results led to the approval of Sugemalimab as the world's first PD-1/PD-L1 inhibitor for the treatment of R/R ENKTL, providing a desperately needed and highly effective new therapeutic option for patients with this challenging disease.[39] The strategic decision to pursue indications like ENKTL, ESCC, and gastric cancer, which have a high incidence in East Asia, demonstrates a well-executed clinical development plan. This approach allowed CStone to achieve multiple first-in-class approvals in its domestic market, establishing Sugemalimab as a standard of care and building a strong clinical and commercial foundation from which to launch its global expansion.

Clinical Efficacy and Safety Across the Therapeutic Spectrum

Efficacy in Approved Indications

The clinical utility of Sugemalimab is defined by its application in practice, including its standardized dosing and its role as both a combination agent and a monotherapy.

• Dosage and Administration: The recommended dose for Sugemalimab across its approved indications is a fixed dose of 1200 mg, administered as a 60-minute intravenous infusion every 3 weeks.[21] This standardized, non-weight-based dosing regimen simplifies clinical practice. Treatment is generally recommended to continue until evidence of disease progression or the occurrence of unacceptable toxicity.[1]
• Role in Combination Therapy: In the majority of its approved indications for solid tumors—metastatic and unresectable NSCLC, gastric cancer, and esophageal cancer—Sugemalimab is indicated for use in combination with a standard-of-care, platinum-based chemotherapy backbone.[2] The specific chemotherapy agents vary by histology and indication, including carboplatin/pemetrexed for non-squamous NSCLC, carboplatin/paclitaxel for squamous NSCLC, CAPOX for gastric cancer, and 5-FU/cisplatin for ESCC.[21] In these settings, Sugemalimab acts synergistically with chemotherapy to enhance the anti-tumor response.
• Role as Monotherapy: In the setting of relapsed/refractory extranodal NK/T-cell lymphoma, Sugemalimab has demonstrated potent efficacy as a single agent.[37] This highlights its intrinsic anti-tumor activity in a hematologic malignancy where the immune system plays a central role in disease pathogenesis.

Comprehensive Safety and Tolerability Profile

Across the GEMSTONE clinical program, Sugemalimab has demonstrated a manageable and predictable safety profile that is consistent with the known class effects of PD-1/PD-L1 inhibitors.[33] Importantly, long-term follow-up from the pivotal GEMSTONE-302 trial did not identify any new or unexpected safety signals, confirming its favorable long-term tolerability.[23]

The most robust safety dataset comes from the GEMSTONE-302 trial in metastatic NSCLC, which provides a clear picture of the adverse event profile when Sugemalimab is added to chemotherapy.

• Common Adverse Events (Any Grade): The most frequently reported side effects of any severity include anemia, elevated liver enzymes (aminotransferases), rash, hyperlipidemia (high blood fat levels), hyperglycemia (high blood glucose), hyponatremia (low sodium), and hypokalemia (low potassium).[2]
• High-Grade (Grade ≥3) Treatment-Related Adverse Events (TRAEs): A key finding from GEMSTONE-302 was that the addition of Sugemalimab to chemotherapy did not substantially increase the overall rate of severe toxicity. The incidence of Grade 3 or 4 TRAEs was comparable between the Sugemalimab-plus-chemotherapy arm and the placebo-plus-chemotherapy arm (56% vs. 57%).[23] This suggests that the incremental toxicity of adding Sugemalimab is minimal, making it an attractive agent for combination regimens. The most common severe TRAEs were primarily hematological and were observed at similar rates in both arms, as detailed in Table 2.
• Serious and Fatal Adverse Events: Treatment-related serious adverse events were reported in 26% of patients receiving Sugemalimab compared to 20% of patients receiving placebo.[23] Treatment-related deaths were infrequent but occurred at a slightly higher rate in the Sugemalimab arm (3%) compared to the placebo arm (1%) in an earlier analysis, with no new treatment-related deaths reported in the long-term follow-up.[23]

Table 2: Summary of Grade ≥3 Treatment-Related Adverse Events (GEMSTONE-302)

Adverse Event (MedDRA Term)	Sugemalimab + Chemo (N=320) %	Placebo + Chemo (N=159) %
Decreased neutrophil count	33%	33%
Decreased white blood cell count	15%	17%
Anemia	14%	11%
Decreased platelet count	11%	9%
All Serious TRAEs	26%	20%
Data compiled from sources.21

The data presented in Table 2 are crucial for clinical decision-making. They quantitatively demonstrate that the primary toxicities associated with the Sugemalimab-chemotherapy combination are driven by the chemotherapy backbone itself, particularly myelosuppression (e.g., neutropenia). The near-identical rates of these events between the two arms provide strong evidence to support the conclusion that Sugemalimab has a manageable safety profile and does not significantly exacerbate the hematologic toxicity of platinum-based chemotherapy.

Global Regulatory Trajectory and Market Access

Sugemalimab's path to market has been characterized by a strategic, region-focused approach, beginning with a comprehensive series of approvals in its domestic market of China, followed by successful entries into major European markets.

Table 3: Global Regulatory Status and Approved Indications for Sugemalimab

Regulatory Agency	Jurisdiction	Approved Indication(s)	Brand Name	Date of Approval / Status
NMPA	China	1. 1L Metastatic (Stage IV) NSCLC 2. Unresectable (Stage III) NSCLC 3. R/R ENKTL 4. 1L ESCC 5. 1L G/GEJ Adenocarcinoma (CPS ≥5)	Cejemly	Dec 2021 Jun 2022 Oct 2023 Dec 2023 Mar 2024
EMA	European Union	1L Metastatic NSCLC (no sensitizing EGFR/ALK/ROS1/RET aberrations)	Cejemly	Jul 2024
MHRA	United Kingdom	1L Metastatic NSCLC (no sensitizing EGFR/ALK/ROS1/RET aberrations)	Eqjubi	Oct 2024
FDA	United States	Breakthrough Therapy Designation (R/R ENKTL) Orphan Drug Designation (T-cell Lymphoma, HCC)	N/A	Not Approved
NMPA: National Medical Products Administration; EMA: European Medicines Agency; MHRA: Medicines and Healthcare products Regulatory Agency; FDA: Food and Drug Administration.

China (NMPA): A Foundation of Multiple Approvals

CStone Pharmaceuticals executed a highly successful regulatory strategy in China, securing five distinct approvals for Sugemalimab in rapid succession, establishing it as a versatile and foundational immuno-oncology therapy in the country.[32]

• December 2021: First approval for the first-line treatment of metastatic (Stage IV) NSCLC.[2]
• June 2022: Approval as a consolidation therapy for patients with unresectable Stage III NSCLC.[2]
• October 2023: Approval for the treatment of relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL).[2]
• December 2023: Approval for the first-line treatment of esophageal squamous cell carcinoma (ESCC).[33]
• March 2024: Approval for the first-line treatment of G/GEJ adenocarcinoma with PD-L1 CPS ≥5.[32]

Europe (EMA) and UK (MHRA): Successful Market Entry

Building on the strength of its clinical data, particularly from the GEMSTONE-302 trial, Sugemalimab has achieved significant regulatory milestones in Europe.

• European Medicines Agency (EMA): Following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on May 30, 2024, the European Commission granted full marketing authorization for Cejemly on July 24, 2024.[2] The approved indication is for the first-line treatment of adults with metastatic NSCLC (in combination with platinum-based chemotherapy) whose tumors lack sensitizing EGFR, ALK, ROS1, or RET genomic aberrations.[20] A subsequent application to expand the label to include the Stage III NSCLC indication is currently under review by the EMA.[49]
• Medicines and Healthcare products Regulatory Agency (MHRA): The UK regulatory body granted approval for Sugemalimab, under the brand name Eqjubi, on October 30, 2024.[2] The indication mirrors that of the EMA, covering the first-line treatment of metastatic NSCLC in combination with chemotherapy.[14]

United States (FDA): A Different Path

As of late 2024, Sugemalimab has not received full marketing approval from the U.S. Food and Drug Administration.[20] This reflects a broader regulatory trend where the FDA has expressed increasing scrutiny over drugs whose pivotal data are generated exclusively or primarily in a single foreign country, such as China, citing concerns about the applicability of such data to the diverse U.S. patient population. This has created a more challenging pathway to the U.S. market for drugs developed under this model. CStone and its partners appear to have adopted a pragmatic strategy, prioritizing approvals in regions like Europe where the regulatory environment for their data package was more favorable.

Despite the absence of a Biologics License Application (BLA) approval, the FDA has recognized the potential of Sugemalimab through several important designations for indications with high unmet medical need:

• Breakthrough Therapy Designation: Granted for the treatment of adult patients with R/R ENKTL.[1]
• Orphan Drug Designation: Granted for the treatment of T-cell lymphoma and for hepatocellular carcinoma.[1]

These designations could facilitate a more streamlined regulatory review if and when a BLA is submitted for these specific, often rare, conditions.

Comparative Assessment and Positioning in the Immuno-Oncology Armamentarium

Efficacy and Safety vs. Other Checkpoint Inhibitors (NSCLC Focus)

In the highly competitive landscape of immune checkpoint inhibitors for NSCLC, Sugemalimab's positioning is defined by its performance relative to established agents like pembrolizumab (a PD-1 inhibitor) and durvalumab (another PD-L1 inhibitor). Network meta-analyses (NMAs) provide a framework for indirect comparisons.

• vs. Pembrolizumab (Anti-PD-1): A network meta-analysis focusing on first-line treatments for advanced squamous NSCLC in Chinese patients provided a direct comparison of efficacy and safety. In this analysis, Sugemalimab was found to be superior to pembrolizumab on measures of both OS (HR 0.48 vs. 0.71) and PFS (HR 0.33 vs. 0.57).[51] In terms of severe (Grade 3-5) adverse events, Sugemalimab also appeared to have a more favorable profile (Odds Ratio 1.11 vs. 1.22).[51] It is important to note that other, broader NMAs have associated both pembrolizumab (vs. chemotherapy) and Sugemalimab (vs. placebo) with an increased risk of severe immune-related adverse events (irAEs), a known class effect.[52]
• vs. Durvalumab (Anti-PD-L1): The most relevant comparison is in the setting of unresectable Stage III NSCLC. Durvalumab's approval, based on the PACIFIC trial, established immunotherapy consolidation as the standard of care but was limited to patients who had received concurrent chemoradiotherapy.[26] Sugemalimab's pivotal GEMSTONE-301 trial was intentionally designed to include a broader population, enrolling patients who had received either concurrent or sequential chemoradiotherapy. By demonstrating a clear survival benefit in both groups, Sugemalimab addresses a significant clinical gap and provides a high-level evidence base for treating patients who are ineligible for or cannot tolerate concurrent therapy, a common real-world scenario.[26]

Strategic Differentiation and Market Position

Sugemalimab has carved out a distinct and competitive position in the global market through a combination of broad applicability, first-in-class achievements, and a favorable safety profile.

• Broad Utility in NSCLC: The consistent efficacy demonstrated in the GEMSTONE-302 trial for first-line metastatic NSCLC, irrespective of PD-L1 expression or tumor histology, is a powerful differentiator.[11] This "all-comer" benefit simplifies clinical practice by potentially obviating the need for PD-L1 biomarker testing for treatment selection, positioning Sugemalimab as a convenient and universally applicable option. This profile as a reliable, broadly effective, and safe combination partner could establish it as a "workhorse" immunotherapy in this setting.
• First-in-Class Approvals: Sugemalimab's status as the world's first anti-PD-L1 antibody approved for R/R ENKTL, first-line ESCC, and first-line G/GEJ adenocarcinoma is a major strategic accomplishment.[32] These approvals establish it as the standard of care in indications with significant unmet needs, particularly in Asia, securing a strong market position before competitors.
• Favorable Combination Safety Profile: The clinical data, especially from GEMSTONE-302, indicate that Sugemalimab can be added to standard chemotherapy regimens without substantially increasing the rate of severe adverse events, particularly hematological toxicities.[23] This predictable and manageable safety profile makes it an attractive partner for combination therapy, a cornerstone of modern cancer treatment.

Future Directions and Expert Conclusion

Ongoing Research and Potential for Label Expansion

The clinical development of Sugemalimab is ongoing, with a clear strategy aimed at maximizing its therapeutic potential through label expansion and exploration of new indications. CStone is actively pursuing regulatory submissions in Europe and other international markets for the indications already approved in China, including Stage III NSCLC, gastric cancer, and ESCC.[14] This effort aims to translate its regional success into a global presence.

The development pipeline for Sugemalimab remains active, with studies investigating its utility in other malignancies. These include Phase I/II trials in liver cancer and other solid tumors, as well as a Phase II study in Hodgkin's disease.[7] Future research will likely focus on moving Sugemalimab into earlier lines of therapy (e.g., neoadjuvant and adjuvant settings) and exploring novel combination strategies with other targeted therapies, immunotherapies, and antibody-drug conjugates to overcome resistance and further improve patient outcomes.

Cost-Effectiveness and Market Access Considerations

While the clinical value of Sugemalimab is well-established, its economic profile presents a more complex picture and highlights a critical challenge for all innovative oncology drugs. Several health economic analyses conducted from the perspective of the Chinese healthcare system have concluded that, at its initial launch price, Sugemalimab in combination with chemotherapy is not a cost-effective option for metastatic NSCLC, Stage III NSCLC, or gastric cancer when measured against standard willingness-to-pay thresholds.[27] These studies suggest that significant price reductions or the implementation of patient assistance programs (PAPs) are necessary to make the therapy economically viable within that system.[27] This underscores the global tension between therapeutic innovation and healthcare sustainability. The long-term commercial success of Sugemalimab, particularly in markets with centralized health technology assessment processes like Europe, will depend heavily on CStone's ability to negotiate pricing and reimbursement agreements that reflect the drug's demonstrated clinical value.

Concluding Remarks and Clinical Perspective

Sugemalimab has emerged as a formidable new entrant in the class of PD-L1 immune checkpoint inhibitors. It is distinguished by a sophisticated and differentiated molecular design that aims to optimize the therapeutic index, a robust and extensive body of clinical evidence from the GEMSTONE program, and a manageable safety profile that makes it a suitable partner for combination chemotherapy.

The drug's development and regulatory strategy has been exemplary, leveraging a "China-first" approach to secure multiple first-in-class approvals in indications with high regional prevalence. This has built a strong foundation for a carefully orchestrated global expansion, which has already resulted in successful market entries in the European Union and the United Kingdom.

Sugemalimab is more than a "me-too" compound; its broad, "all-comer" efficacy in NSCLC and its unique approvals in ENKTL, ESCC, and gastric cancer have already reshaped clinical practice and established new standards of care. Its future global impact will be contingent on its ability to navigate the complex U.S. regulatory landscape, demonstrate compelling value in health economic assessments to secure broad market access, and continue to generate innovative data in new therapeutic settings. Ultimately, Sugemalimab stands as a testament to the maturation of the global biopharmaceutical industry and a clear indicator of the increasing influence of scientifically driven innovation from China on the world stage.

Works cited

1. Sugemalimab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 7, 2025, https://go.drugbank.com/drugs/DB16641
2. Sugemalimab - Wikipedia, accessed September 7, 2025, https://en.wikipedia.org/wiki/Sugemalimab
3. Sugemalimab | Anti-PD-L1 Antibody - MedchemExpress.com, accessed September 7, 2025, https://www.medchemexpress.com/sugemalimab.html
4. Sugemalimab | CAS NO.:2256084-03-2 - GlpBio, accessed September 7, 2025, https://www.glpbio.com/sugemalimab.html
5. Sugemalimab | CAS 2256084-03-2 | AbMole BioScience, accessed September 7, 2025, https://www.abmole.com/products/sugemalimab.html
6. Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) - Selleck Chemicals, accessed September 7, 2025, https://www.selleckchem.com/products/sugemalimab-anti-b7-h1-pd-l1-cd274.html
7. Sugemalimab: First Approval - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/35298827/
8. Sugemalimab | C6H11ClN2 | CID 13444038 - PubChem, accessed September 7, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/13444038
9. SUGEMALIMAB - Inxight Drugs, accessed September 7, 2025, https://drugs.ncats.io/substance/90IQR2I6TR
10. CStone announces the GEMSTONE-302 study of sugemalimab met ..., accessed September 7, 2025, https://www.cstonepharma.com/en/html/news/2738.html
11. European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC-CStone Pharmaceuticals, accessed September 7, 2025, https://www.cstonepharma.com/en/html/news/3702.html
12. Sugemalimab - CStone Pharmaceuticals/EQRx - AdisInsight - Springer, accessed September 7, 2025, https://adisinsight.springer.com/drugs/800048100
13. What is the mechanism of Sugemalimab?, accessed September 7, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-sugemalimab
14. CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK, accessed September 7, 2025, https://www.cstonepharma.com/en/html/news/3747.html
15. CStone Pharmaceuticals - HKEXnews, accessed September 7, 2025, https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1031/2024103100533.pdf
16. CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK APAC - PR Newswire, accessed September 7, 2025, https://www.prnewswire.com/apac/news-releases/cstone-announces-mhra-approval-of-sugemalimab-for-first-line-treatment-of-non-small-cell-lung-cancer-nsclc-in-the-uk-302292383.html
17. Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/384809374_Comprehensive_population_pharmacokinetic_modelling_of_sugemalimab_an_anti-programmed_death-ligand_1_PD-L1_human_monoclonal_antibody_in_patients_with_solid_tumours_or_lymphomas_across_multiple_Phase_I-
18. Comprehensive population pharmacokinetic modelling of ... - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/39389094/
19. Introduction to Pharmacokinetics and Pharmacodynamics - ASHP, accessed September 7, 2025, https://www.ashp.org/-/media/store%20files/p2418-sample-chapter-1.pdf
20. Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first‑line treatment of metastatic non‑small‑cell lung cancer (NSCLC) - Repository of AIHTA GmbH, accessed September 7, 2025, https://eprints.aihta.at/1521/1/Fact%20Sheet%20Nr.177.pdf
21. Sugemalimab Plus Chemotherapy Demonstrates Durable Efficacy as First-Line Treatment in Metastatic NSCLC - Targeted Oncology, accessed September 7, 2025, https://www.targetedonc.com/view/sugemalimab-plus-chemotherapy-demonstrates-durable-efficacy-as-first-line-treatment-in-metastatic-nsclc
22. Promising Outlook for Sugemalimab in Non-Small-Cell Lung Cancer, accessed September 7, 2025, https://www.mdalert.com/learning/alc-NSCLC/promising-outlook-for-sugemalimab
23. Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC - The ASCO Post, accessed September 7, 2025, https://ascopost.com/news/july-2025/extended-outcomes-with-addition-of-sugemalimab-to-first-line-chemotherapy-in-metastatic-nsclc/
24. Multimed Packaging Shown to Improve Medication Adherence, accessed September 7, 2025, https://www.targetedonc.com/view/sugemalimab-chemo-shows-durable-survival-benefit-in-first-line-metastatic-nsclc
25. Long-Term Survival Data of GEMSTONE-302 Trial on Sugemalimab ..., accessed September 7, 2025, https://www.cstonepharma.com/en/html/news/3818.html
26. Sugemalimab Shows Efficacy as Consolidation Therapy in Unresectable Stage III NSCLC, accessed September 7, 2025, https://www.onclive.com/view/sugemalimab-shows-efficacy-as-consolidation-therapy-in-unresectable-stage-iii-nsclc
27. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10234548/
28. GEMSTONE-303 Trial Shows Sugemalimab Plus Chemotherapy Significantly Improves Survival in Advanced Gastric Cancer, accessed September 7, 2025, https://www.appliedclinicaltrialsonline.com/view/gemstone-trial-sugemalimab--survival-advanced-gastric-cancer
29. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/39992668/
30. CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA - PR Newswire, accessed September 7, 2025, https://www.prnewswire.com/news-releases/cstone-announces-publication-of-gemstone-303-study-results-for-sugemalimab-cejemly-in-jama-302384091.html
31. A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma - larvol clin, accessed September 7, 2025, https://clin.larvol.com/trial-detail/NCT03802591
32. CStone Announces the Fifth Indication Approved for Sugemalimab ..., accessed September 7, 2025, https://www.prnewswire.com/apac/news-releases/cstone-announces-the-fifth-indication-approved-for-sugemalimab-in-china-as-first-line-treatment-for-gastric-cancer-302090096.html
33. CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma - FirstWord Pharma, accessed September 7, 2025, https://firstwordpharma.com/story/5809300
34. CStone Announces NMPA Approval of Sugemalimab as First-line ..., accessed September 7, 2025, https://www.cstonepharma.com/en/html/news/3644.html
35. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma - larvol clin, accessed September 7, 2025, https://clin.larvol.com/trial-detail/NCT04187352
36. CStone's Sugemalimab Granted NMPA Approval for Esophageal Cancer, accessed September 7, 2025, https://biopharmaapac.com/news/79/4039/cstones-sugemalimab-granted-nmpa-approval-for-esophageal-cancer.html
37. Sugemalimab Receives Approval in China for Relapsed/Refractory Extranodal NK/T-cell Lymphoma - OncLive, accessed September 7, 2025, https://www.onclive.com/view/sugemalimab-receives-approval-in-china-for-relapsed-refractory-extranodal-nk-t-cell-lymphoma
38. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study - ASCO Publications, accessed September 7, 2025, https://ascopubs.org/doi/10.1200/JCO.22.02367
39. The new indication for Sugemalimab has been approved in China, making it the world's first treatment for R/R ENKTL - Patsnap Synapse, accessed September 7, 2025, https://synapse.patsnap.com/blog/the-new-indication-for-sugemalimab-has-been-approved-in-china-making-it-the-worlds-first-treatment-for-rr-enktl
40. CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication - PR Newswire, accessed September 7, 2025, https://www.prnewswire.com/apac/news-releases/cstone-announces-nmpa-approval-of-sugemalimab-for-patients-with-relapsed-or-refractory-extranodal-nkt-cell-lymphoma-the-first-anti-pd-1pd-l1-mab-approved-for-this-indication-301972127.html
41. Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line ..., accessed September 7, 2025, https://www.onclive.com/view/sugemalimab-plus-chemotherapy-earns-uk-approval-in-first-line-metastatic-nsclc
42. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/34984540/
43. Sugemalimab approved to treat adult patients with non-small cell ..., accessed September 7, 2025, https://www.gov.uk/government/news/sugemalimab-approved-to-treat-adult-patients-with-non-small-cell-lung-cancer
44. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/40523368/
45. Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC, accessed September 7, 2025, https://www.cancernetwork.com/view/sugemalimab-chemotherapy-improves-long-term-survival-in-metastatic-nsclc
46. Cejemly | European Medicines Agency (EMA), accessed September 7, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cejemly
47. CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress, accessed September 7, 2025, https://firstwordpharma.com/story/5945540
48. EMA Recommends Granting a Marketing Authorisation for Sugemalimab | ESMO, accessed September 7, 2025, https://www.esmo.org/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-sugemalimab
49. EMA to Review Application for Expanded Indication for Sugemalimab in Unresectable NSCLC - OncLive, accessed September 7, 2025, https://www.onclive.com/view/ema-to-review-application-for-expanded-indication-for-sugemalimab-in-unresectable-nsclc
50. MHRA approves CStone Pharmaceuticals' sugemalimab to treat lung cancer in adults, accessed September 7, 2025, https://pmlive.com/pharma_news/mhra-approves-cstone-pharmaceuticals-sugemalimab-to-treat-lung-cancer-in-adults/
51. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of ..., accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9558711/
52. Comparative efficacy and safety of first‑line PD‑1/PD‑L1 inhibitors in immunotherapy for non‑small cell lung cancer: A network meta‑analysis - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11799748/
53. Sugemalimab Completed Phase 1 Trials for Advanced Solid Tumors Treatment - DrugBank, accessed September 7, 2025, https://go.drugbank.com/drugs/DB16641/clinical_trials?conditions=DBCOND0030110&phase=1&purpose=treatment&status=completed
54. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China - Frontiers, accessed September 7, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1081750/full
55. Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5 - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/394870006_Cost-effective_analysis_of_sugemalimab_plus_chemotherapy_as_first-line_treatment_for_advanced_gastric_or_gastroesophageal_junction_adenocarcinoma_with_PD-L1_CPS_5